Buscar
NewAmsterdam Pharma Company NV
NAMSWAñadir a la lista de seguimiento
24.890USD
+1.450+6.19%
Cierre 07/07, 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de NewAmsterdam Pharma Company NV Compañía
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Información de NewAmsterdam Pharma Company NV
Símbolo de cotizaciónNAMSW
Nombre de la empresaNewAmsterdam Pharma Company NV
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
DirecciónGooimeer 2-35
CiudadNAARDEN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal1411 DC
Teléfono31352062971
Sitio Webhttps://ir.newamsterdampharma.com/
Símbolo de cotizaciónNAMSW
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Ejecutivos de NewAmsterdam Pharma Company NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
--
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
--
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de NewAmsterdam Pharma Company NV?
Los cinco principales accionistas de NewAmsterdam Pharma Company NV son: Mr. William H. (Will) Lewis, J.D.